Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $AMRX vs $AXSM | Chartloom

Compare

$AMRX vs $AXSM

Amneal Pharmaceuticals Inc · Axsome Therapeutics Inc

AMRX

Amneal Pharmaceuticals Inc

AXSM

Axsome Therapeutics Inc

Compare $AMRX vs $AXSM

Comparing Amneal Pharmaceuticals Inc and Axsome Therapeutics Inc

AMRXAmneal Pharmaceuticals Inc

AXSMAxsome Therapeutics Inc

AMRXAmneal Pharmaceuticals Inc

Market cap

$6.25B

P/E (TTM)

40.80x

Forward P/E (NTM)

19.08x

Forward P/S (NTM)

1.89x

Rev growth (TTM)

9.3%

YTD performance

54.6%

52W performance

96.3%

FCF yield

-0.2%

AXSMAxsome Therapeutics Inc

Market cap

$8.04B

P/E (TTM)

—

Forward P/E (NTM)

211.90x

Forward P/S (NTM)

6.58x

Rev growth (TTM)

56.9%

YTD performance

-12.5%

52W performance

28.4%

FCF yield

-0.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AMRX

AXSM

Detailed metrics comparison

AMRX

Amneal Pharmaceuticals Inc

AXSM

Axsome Therapeutics Inc

Market Cap

AMRX$6.25B

AXSM$8.04B

Enterprise Value

AMRX$8.85B

AXSM$7.93B

Price

AMRX$19.57

AXSM$156.32

P/E Ratio

AMRX40.80x

AXSMN/A

P/S Ratio

AMRX2.00x

AXSM10.36x

EV/Sales

AMRX2.84x

AXSM10.21x

EV/EBITDA

AMRX13.14x

AXSM0.00x

P/B Ratio

AMRX192.54x

AXSM105.86x

P/FCF Ratio

AMRXN/A

AXSMN/A

EV/FCF

AMRX-719.11x

AXSM-110.16x

PEG Ratio

AMRX1.98x

AXSMN/A

Forward P/E (NTM)

AMRX19.08x

AXSM211.90x

Forward P/S (NTM)

AMRX1.89x

AXSM6.58x

Revenue (TTM)

AMRX$3.12B

AXSM$777M

Revenue Growth (YoY)

AMRX9.3%

AXSM56.9%

Forward Rev Growth

AMRX9.0%

AXSM59.9%

Gross Margin (TTM)

AMRX39.3%

AXSM93.2%

Operating Margin (TTM)

AMRX14.6%

AXSM0.0%

EBITDA Margin (TTM)

AMRX21.6%

AXSM-23.0%

Net Margin (TTM)

AMRX5.0%

AXSM-24.7%

FCF Margin (TTM)

AMRX-0.4%

AXSM-9.3%

Net Income (TTM)

AMRX$157M

AXSM$-192M

FCF (TTM)

AMRX$-12M

AXSM$-72M

EPS (TTM)

AMRX$0.48

AXSM-$3.70

ROE (TTM)

AMRX174.6%

AXSM-25560.0%

ROA (TTM)

AMRX4.3%

AXSM-2705.0%

ROIC (TTM)

AMRX2.1%

AXSM-7042.0%

Cash

AMRX$128M

AXSM$320M

Debt

AMRX$2.73B

AXSM$202M

Net Cash/Debt

AMRX$-2.60B

AXSM$117M

Current Ratio (TTM)

AMRX2.20x

AXSM1.43x

Quick Ratio (TTM)

AMRX1.38x

AXSM1.30x

Debt/Equity (TTM)

AMRX82.62x

AXSM2.43x

Debt/Assets (TTM)

AMRX0.0%

AXSM0.0%

Interest Coverage (TTM)

AMRXN/A

AXSMN/A

Net Debt/EBITDA (TTM)

AMRX0.00x

AXSM0.00x

Beta

AMRX1.22

AXSM0.79

52W Performance

AMRX96.3%

AXSM28.4%

YTD Performance

AMRX54.6%

AXSM-12.5%

% from 52W High

AMRX-7.6%

AXSM-39.9%

% from 52W Low

AMRX104.7%

AXSM31.1%

Asset Turnover (TTM)

AMRX0.85x

AXSM1.10x

FCF Yield (TTM)

AMRX-0.2%

AXSM-0.9%

Earnings Yield (TTM)

AMRX2.5%

AXSM-2.4%

Dividend Yield (TTM)

AMRXN/A

AXSMN/A

Rule of 40

AMRX8.9

AXSM47.6

EV/GP/RG

AMRX1.16

AXSM0.19

Ticker research

View AMRX research View AXSM research

Metric	AMRX Amneal Pharmaceuticals Inc	AXSM Axsome Therapeutics Inc
Market & Valuation
Market Cap	$6.25B	$8.04B
Enterprise Value	$8.85B	$7.93B
Price	$19.57	$156.32
P/E Ratio	40.80x	N/A
P/S Ratio	2.00x	10.36x
EV/Sales	2.84x	10.21x
EV/EBITDA	13.14x	0.00x
P/B Ratio	192.54x	105.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-719.11x	-110.16x
PEG Ratio	1.98x	N/A
Forward P/E (NTM)	19.08x	211.90x
Forward P/S (NTM)	1.89x	6.58x
Revenue & Growth
Revenue (TTM)	$3.12B	$777M
Revenue Growth (YoY)	9.3%	56.9%
Forward Rev Growth	9.0%	59.9%
Profitability
Gross Margin (TTM)	39.3%	93.2%
Operating Margin (TTM)	14.6%	0.0%
EBITDA Margin (TTM)	21.6%	-23.0%
Net Margin (TTM)	5.0%	-24.7%
FCF Margin (TTM)	-0.4%	-9.3%
Net Income (TTM)	$157M	$-192M
FCF (TTM)	$-12M	$-72M
EPS (TTM)	$0.48	-$3.70
ROE (TTM)	174.6%	-25560.0%
ROA (TTM)	4.3%	-2705.0%
ROIC (TTM)	2.1%	-7042.0%
Financial Health
Cash	$128M	$320M
Debt	$2.73B	$202M
Net Cash/Debt	$-2.60B	$117M
Current Ratio (TTM)	2.20x	1.43x
Quick Ratio (TTM)	1.38x	1.30x
Debt/Equity (TTM)	82.62x	2.43x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.22	0.79
52W Performance	96.3%	28.4%
YTD Performance	54.6%	-12.5%
% from 52W High	-7.6%	-39.9%
% from 52W Low	104.7%	31.1%
Efficiency & Yields
Asset Turnover (TTM)	0.85x	1.10x
FCF Yield (TTM)	-0.2%	-0.9%
Earnings Yield (TTM)	2.5%	-2.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	8.9	47.6
EV/GP/RG	1.16	0.19
Ticker research	View AMRX research	View AXSM research

Valuation

P/E Ratio

AMRX

40.80x

P/S Ratio

AMRX

2.00x

AXSM

10.36x

EV/FCF

AMRX

-719.11x

AXSM

-110.16x

Growth & revenue

Revenue Growth TTM

AXSM

56.9%

AMRX

9.3%

Forward Revenue Growth

AXSM

59.9%

AMRX

9.0%

Profitability & performance

Gross Margin

AXSM

93.2%

AMRX

39.3%

ROE

AMRX

174.6%

AXSM

-25560.0%

FCF Yield %

AMRX

-0.2%

AXSM

-0.9%

52-Week Performance

AMRX

96.3%

AXSM

28.4%

Detailed metrics comparison

AMRX

Amneal Pharmaceuticals Inc

AXSM

Axsome Therapeutics Inc

Market Cap

AMRX$6.25B

AXSM$8.04B

Enterprise Value

AMRX$8.85B

AXSM$7.93B

Price

AMRX$19.57

AXSM$156.32

P/E Ratio

AMRX40.80x

AXSMN/A

P/S Ratio

AMRX2.00x

AXSM10.36x

EV/Sales

AMRX2.84x

AXSM10.21x

EV/EBITDA

AMRX13.14x

AXSM0.00x

P/B Ratio

AMRX192.54x

AXSM105.86x

P/FCF Ratio

AMRXN/A

AXSMN/A

EV/FCF

AMRX-719.11x

AXSM-110.16x

PEG Ratio

AMRX1.98x

AXSMN/A

Forward P/E (NTM)

AMRX19.08x

AXSM211.90x

Forward P/S (NTM)

AMRX1.89x

AXSM6.58x

Revenue (TTM)

AMRX$3.12B

AXSM$777M

Revenue Growth (YoY)

AMRX9.3%

AXSM56.9%

Forward Rev Growth

AMRX9.0%

AXSM59.9%

Gross Margin (TTM)

AMRX39.3%

AXSM93.2%

Operating Margin (TTM)

AMRX14.6%

AXSM0.0%

EBITDA Margin (TTM)

AMRX21.6%

AXSM-23.0%

Net Margin (TTM)

AMRX5.0%

AXSM-24.7%

FCF Margin (TTM)

AMRX-0.4%

AXSM-9.3%

Net Income (TTM)

AMRX$157M

AXSM$-192M

FCF (TTM)

AMRX$-12M

AXSM$-72M

EPS (TTM)

AMRX$0.48

AXSM-$3.70

ROE (TTM)

AMRX174.6%

AXSM-25560.0%

ROA (TTM)

AMRX4.3%

AXSM-2705.0%

ROIC (TTM)

AMRX2.1%

AXSM-7042.0%

Cash

AMRX$128M

AXSM$320M

Debt

AMRX$2.73B

AXSM$202M

Net Cash/Debt

AMRX$-2.60B

AXSM$117M

Current Ratio (TTM)

AMRX2.20x

AXSM1.43x

Quick Ratio (TTM)

AMRX1.38x

AXSM1.30x

Debt/Equity (TTM)

AMRX82.62x

AXSM2.43x

Debt/Assets (TTM)

AMRX0.0%

AXSM0.0%

Interest Coverage (TTM)

AMRXN/A

AXSMN/A

Net Debt/EBITDA (TTM)

AMRX0.00x

AXSM0.00x

Beta

AMRX1.22

AXSM0.79

52W Performance

AMRX96.3%

AXSM28.4%

YTD Performance

AMRX54.6%

AXSM-12.5%

% from 52W High

AMRX-7.6%

AXSM-39.9%

% from 52W Low

AMRX104.7%

AXSM31.1%

Asset Turnover (TTM)

AMRX0.85x

AXSM1.10x

FCF Yield (TTM)

AMRX-0.2%

AXSM-0.9%

Earnings Yield (TTM)

AMRX2.5%

AXSM-2.4%

Dividend Yield (TTM)

AMRXN/A

AXSMN/A

Rule of 40

AMRX8.9

AXSM47.6

EV/GP/RG

AMRX1.16

AXSM0.19

Ticker research

View AMRX research View AXSM research

Metric	AMRX Amneal Pharmaceuticals Inc	AXSM Axsome Therapeutics Inc
Market & Valuation
Market Cap	$6.25B	$8.04B
Enterprise Value	$8.85B	$7.93B
Price	$19.57	$156.32
P/E Ratio	40.80x	N/A
P/S Ratio	2.00x	10.36x
EV/Sales	2.84x	10.21x
EV/EBITDA	13.14x	0.00x
P/B Ratio	192.54x	105.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-719.11x	-110.16x
PEG Ratio	1.98x	N/A
Forward P/E (NTM)	19.08x	211.90x
Forward P/S (NTM)	1.89x	6.58x
Revenue & Growth
Revenue (TTM)	$3.12B	$777M
Revenue Growth (YoY)	9.3%	56.9%
Forward Rev Growth	9.0%	59.9%
Profitability
Gross Margin (TTM)	39.3%	93.2%
Operating Margin (TTM)	14.6%	0.0%
EBITDA Margin (TTM)	21.6%	-23.0%
Net Margin (TTM)	5.0%	-24.7%
FCF Margin (TTM)	-0.4%	-9.3%
Net Income (TTM)	$157M	$-192M
FCF (TTM)	$-12M	$-72M
EPS (TTM)	$0.48	-$3.70
ROE (TTM)	174.6%	-25560.0%
ROA (TTM)	4.3%	-2705.0%
ROIC (TTM)	2.1%	-7042.0%
Financial Health
Cash	$128M	$320M
Debt	$2.73B	$202M
Net Cash/Debt	$-2.60B	$117M
Current Ratio (TTM)	2.20x	1.43x
Quick Ratio (TTM)	1.38x	1.30x
Debt/Equity (TTM)	82.62x	2.43x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.22	0.79
52W Performance	96.3%	28.4%
YTD Performance	54.6%	-12.5%
% from 52W High	-7.6%	-39.9%
% from 52W Low	104.7%	31.1%
Efficiency & Yields
Asset Turnover (TTM)	0.85x	1.10x
FCF Yield (TTM)	-0.2%	-0.9%
Earnings Yield (TTM)	2.5%	-2.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	8.9	47.6
EV/GP/RG	1.16	0.19
Ticker research	View AMRX research	View AXSM research